Objectives: We examined the experiences of heart transplant recipients receiving everolimus as maintenance therapy in different combinations over a long time. (14), and ongoing cellular rejection (7). Combinations were either along with cyclosporine (24), mycophenolate mofetil (14), or others (2). Indications for the introduction of everolimus including safety, efficacy, different combinations of everolimus, biopsy-proven acute rejections, renal function, and infections were evaluated retrospectively. Results: Five patients died, 4 of them were still on everolimus at the time of death; they died from intracerebral hemorrhage (1), embolism (1), cardiac arrest (2), and unknown (1). Everolimus was discontinued in 6 patients owing to severe adverse effects: Edema (2), gastrointestinal adverse effects (3), and dermal adverse effects (1). Mean everolimus trough levels were 5.8 µmol/L at 6 months and 4.9 at 60 months. Mean cyclosporine levels were 67.62 µmol/L at 6 months and 47.3 µmol/L at 60 months. Mean serum creatinine levels were stable (147.9 µmol/L after 60 months). Four life-threatening infections (all pneumonia) occurred but resulted in complete recovery. Conclusions: Everolimus is safe with different immunosuppressive combinations after receiving a heart transplant.
Introduction
The development of new immunosuppressive agents has resulted in good long-term survival rates in the majority of heart transplant recipients. Adverse effects of immunosuppressives (mainly steroids and calcineurin inhibitors) are some of the limiting factors affecting patient survival and quality-of-life, aside from cardiac allograft vasculopathy and malignancy. Proliferation signal inhibitors, such as rapamycin and everolimus (EvA) as alternative immunosuppressive regimens may increase longterm survival after one has a heart transplant.
Eisen and associates showed the efficacy and safety of de novo EvA compared with azathioprine in adult heart transplant recipients. 1 Their study reported a delay in development and progression of cardiac allograft vasculopathy but found a worsening in renal function when EvA was combined with fixed-dosage cyclosporine. For that reason, Food and Drug Administration (FDA) approval was refused; however, the European Medicine Agency approved EvA for further studies in 2004. 2 In a prospective, multicenter study, Lehmkuhl and associates demonstrated the possibility of dosage reduction of cyclosporine combined with EvA that resulted in stable renal function without loss of efficacy. 3 Further studies have confirmed these results and additional favorable effects of EvA. [4] [5] [6] This study sought to present EvA as maintenance therapy for different indications and combinations over 5 years in heart transplant recipients.
Materials and Methods

collective patients
Data from 40 patients (29 men, 11 women) who underwent a heart transplant done at the Medical University Graz, Division of Transplantation Surgery, were analyzed retrospectively. Patients who were switched to an EvA-based therapy as a maintenance immunosuppressive regimen (at least 3 months after the heart transplant) were included. Exclusion criteria were patients who were under 18 years of age, combined solid organ transplant recipients, and patients receiving EvA as de novo therapy. We evaluated the introduction of EvA for safety, efficacy, different combinations of EvA, biopsy-proven acute rejections, renal function, and infections. Overall patient characteristics at baseline are summarized in Table 1 . All protocols were approved by the ethics committee of the institution before the study began, and they conformed with the ethical guidelines of the 1975 Helsinki Declaration.
Immunosuppressive regimen
All heart transplant recipients received induction therapy with antilymphocyte globulin for 7 days followed by a triple-drug immunosuppressive therapy including cyclosporine, mycophenolate mofetil, and prednisolone.
Intravenous administration of cyclosporine was given at a dosage of 1.5 mg to 2 per 1000 grams per day. Within 2 to 5 days, intravenous cyclosporine therapy was switched to oral administration (4 mg to 8mg per 1000 g per day), if necessary, by nasogastric tube. Targeted cyclosporine trough levels were 166 to 208 μmol/L (months 1 to 3), 124 to 166 μmol/L (months 3 to 6), 104 to 124 μmol/L (months 6 to 12), and above 83 μmol/L thereafter. When cyclosporine was combined with EvA, targeted trough levels were 100 to 150 (months 3 to 6), and after 6 months, 41 to 83 μmol/L.
Mycophenolate mofetil was started at a dosage of 1000 mg twice a day without trough level controls. Mycophenolate mofetil was reduced if gastrointestinal adverse effects occurred or blood count dropped. Prednisolone was started at 15 mg/d and tapered to 5 mg/d over 6 months.
Everolimus was introduced at 1.0 mg to 1.5 mg daily administered in 2 equal dosages orally. Drug administration was adapted to trough levels between 3.1 μmol/L and 8.3 μmol/L. The immunosuppressive drug to be replaced (mycophenolate mofetil, cyclosporine, or other) was withdrawn within 4 days, beginning with a dosage reduction at day 2 after switching to EvA.
Everolimus, cyclosporine trough levels, blood count, and routine laboratory values were controlled after 1 week and thereafter at routine ambulatory visits when clinically indicated, but at least monthly.
Safety, rejection surveillance
Endomyocardial biopsies were performed weekly during the first month after surgery and monthly during the first 6 months after the heart transplant. Then, the intervals were extended stepwise: After the first year, endomyocardial biopsies were performed annually. Additional endomyocardial biopsies were performed when clinically indicated. Histologic severity was graded according to the revised criteria of The International Society for Heart and Lung Transplantation. 7 Rejections classified greater than 2R were treated with steroids or polyclonal antibodies. 
Statistical Analyses
Obtained data were entered in a protocol Excel spreadsheet, and further statistical analyses were performed with SPSS software (SPSS: An IBM Company, version 15.0, IBM Corporation, Armonk, New York, USA). Data are given as descriptive statistics as mean values ± standard deviation (SD).
Results
collective patients
Between 2004 and 2009, forty patients (29 men, 11 women; mean age, 51.6 y) were switched from other immunosuppressive protocols to an EvA-based immunosuppressive regimen. Indications for conversion to EvA are shown in Table 1 . Everolimus was combined with cyclosporine in 24 patients (20 men, 4 women), with mycophenolate mofetil in 14 patients (9 men, 5 women), in 1 woman with cyclosporine and mycophenolate mofetil, and in 1 woman with tacrolimus and prednisolone.
Five patients (3 men and 2 women) died, 4 of them were still receiving EvA treatment at the time of death. Reasons for death are available in Table 2 . None of the deaths could be correlated to EvA. Everolimus had to be discontinued in 6 patients (14.6%; 5 men and 1 woman) owning to severe adverse effects (see Table  2 ). The patient on tacrolimus was switched to cyclosporine without problems after 6 months of EvA conversion; this was due to greater experience of the physician team with EvA and cyclosporine combination. This patient had no immunosuppressive adverse effects for 6 months or thereafter. Tacrolimus through levels were between 5 to 9 ng/mL. No renal impairment was observed. Follow-up of the patients after 60 months, by indication, is shown in Table 2 . efficacy Targeted EvA trough levels were reached within 1 week for all patients. Mean EvA levels were between 5.1 μmol/L and 5.8 μmol/L, cyclosporine levels between 67.6 to 47.3 μmol/L within 60 months (see Figure 1 ). There were no hemodynamically comprising rejection episodes or biopsy-proven acute rejections greater than 1R.
In the collective 7 patients that were converted to EvA owing to ongoing rejection, acute cellular rejection was diagnosed at a median of 4.1 ± 2.8 years (range, 0.3 to 8 y) after orthotopic heart transplant. Immunosuppressive trough levels in these patients were within the target area. All patients switched to EvA owing to ongoing cellular rejection were combined with cyclosporine and showed no further rejection episodes greater 1R. For baseline cyclosporine trough levels, as well as 60-month follow-up, cyclosporine and EvA trough levels in these patients are shown in Tables 1 and 3 . 
Safety
None of the patients died of infection. Four lifethreatening infections, all pneumonia resulting in a complete recovery, were noticed (all combined with cyclosporine). Infections occurred 3 months (n=1), 4 months (n=1), 12 months (n=1), and 4 years (n=1) after introduction of EvA. In all cases, EvA was paused during the infection. In 2 patients, pneumonia was classified as interstitial pneumonia (4.8%). Everolimus trough levels were above the range in both patients (11.2 μmol/L, 9.6 μmol/L).
For that reason, EvA was reintroduced after recovery, and no further episode of pneumonia occurred. Two cytomegalovirus infections were noticed, although the patient receiving EvA as treatment for recurrent cytomegalovirus infections remained free of any clinical recurrence of cytomegalovirus.
Mean serum creatinine levels increased slightly from 151.64 ± 67.184 μmol/L before conversion to 171.496 ± 82.212 μmol/L after 5 years. Within 60 months, 4 patients were placed on hemodialysis: 2 on cyclosporine (creatinine levels before the switch, 159.12 μmol/L, 307.632 μmol/L) and 2 on mycophenolate mofetil (creatinine levels before the switch, 244.868 μmol/L and 353.6 μmol/L). One patient received kidney transplant.
Hemoglobin, cholesterol, triglycerides, leucocytes, and platelet counts for baseline and after 60 months are shown in Tables 1 and 2 . Only triglyceride levels were above normal during followup, and rose from a mean of 2.16395 mmol/L to 2.71652 mmol/L over 5 years.
Discussion
So far, EvA has been used mainly with cyclosporine, and results to 5 years are limited. In this observational study, no patient was lost owing to conversion to EvA. Most of the adverse effects were controllable. There seems to be some good arguments for converting to EvA. The best documented is cardiac allograft vasculopathy, already reported in 2003 by Eisen and colleagues. 1, 8 Owing to its antiproliferative effect, EvA is also used in oncologic patients with renal carcinoma, pancreatic cancer, and neuroendocrine tumors. [9] [10] [11] Mycophenolate mofetil has been reported to have antiproliferative effects. Everolimus and mycophenolate mofetil combined might hinder too fast the spread of malignancy and become an interesting combination. [9] [10] [11] [12] In our observation, during these 5 years, we did not see any de novo malignancy in these patients. One patient converted to EvA owing to a malignancy had to discontinue EvA owing to severe adverse effects.
In heart transplant recipients at risk of developing end-stage renal failure caused by nephrotoxic adverse effects, EvA may be combined with reduced cyclosporine trough levels; or even more-promising, combined with mycophenolate mofetil. In this study, patients with higher creatinine value before conversion were more likely to receive EvA combined with mycophenolate mofetil (158.6 ± 80 μmol/L) than they were with EvA and cyclosporine (122.7 ± 39.6 μmol/L). When combined with cyclosporine, creatinine values rose to 160.1 ± 81.5 μmol/L after 5 years; whereas in combination with mycophenolate mofetil, creatinine values declined to 129.6 ± 18.3 μmol/L (see Figure 2) . The results are strengthened by the findings of Rothenburger and colleagues. 13 These results led to a new internal policy at our center: Heart transplant recipients with renal impairment are switched to EvA combined with mycophenolate mofetil.
The effectiveness of EvA combined with reduced cyclosporine trough levels for acute cellular rejection has been reported. 1, 3, 6, 14 In this study, 7 patients with ongoing cellular rejection episodes ranging from 3 months to 8 years after a heart transplant received EvA. Most of the patients were 2 years post-heart transplant; only two were 7 and 8 years after a heart transplant. It is unusual to have such late rejections episodes, and we do not have a comprehensive Careful attention must be paid to avoid overimmunosuppression mainly when EvA is combined with cyclosporine, as these drugs may enhance toxicity. In this study, 2 patients had interstitial pneumonia, which was linked to EvA treatment. 15, 16 After pausing EvA during acute infection, EvA was continued in all patients without any recurrence of life-threatening infections. Everolimus has been approved by the FDA to prevent organ rejection in adult kidney transplant recipients, but it is still under investigation for its use in heart transplants. Everolimus is increasingly used in combination with cyclosporine in European countries. Even in different combinations, EvA may be an alternative immunosuppressive drug in maintenance therapy with good results over 5 years. 
